• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

N6-甲基腺嘌呤 RNA 甲基化表观遗传修饰与糖尿病微血管并发症。

N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications.

机构信息

Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.

出版信息

Front Endocrinol (Lausanne). 2024 Sep 4;15:1462146. doi: 10.3389/fendo.2024.1462146. eCollection 2024.

DOI:10.3389/fendo.2024.1462146
PMID:39296713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11408340/
Abstract

N6-methyladensine (mA) has been identified as the best-characterized and the most abundant mRNA modification in eukaryotes. It can be dynamically regulated, removed, and recognized by its specific cellular components (respectively called "writers," "erasers," "readers") and have become a hot research field in a variety of biological processes and diseases. Currently, the underlying molecular mechanisms of mA epigenetic modification in diabetes mellitus (DM) and diabetic microvascular complications have not been extensively clarified. In this review, we focus on the effects and possible mechanisms of mA as possible potential biomarkers and therapeutic targets in the treatment of DM and diabetic microvascular complications.

摘要

N6-甲基腺苷（mA）已被确定为真核生物中研究最为透彻和含量最丰富的 mRNA 修饰物。mA 可以被其特定的细胞成分动态调控、移除和识别（分别称为“writers”、“erasers”、“readers”），并已成为多种生物学过程和疾病的热门研究领域。目前，糖尿病（DM）及其微血管并发症中 mA 表观遗传修饰的潜在分子机制尚未得到广泛阐明。在这篇综述中，我们重点探讨了 mA 作为 DM 和糖尿病微血管并发症治疗中潜在的生物标志物和治疗靶点的作用及其可能的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bf/11408340/46002b73bfc0/fendo-15-1462146-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bf/11408340/54ca42e2fea3/fendo-15-1462146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bf/11408340/46002b73bfc0/fendo-15-1462146-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bf/11408340/54ca42e2fea3/fendo-15-1462146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bf/11408340/46002b73bfc0/fendo-15-1462146-g002.jpg

相似文献

1
N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications.N6-甲基腺嘌呤 RNA 甲基化表观遗传修饰与糖尿病微血管并发症。
Front Endocrinol (Lausanne). 2024 Sep 4;15:1462146. doi: 10.3389/fendo.2024.1462146. eCollection 2024.
2
N6-methyladenine RNA Methylation Epigenetic Modification and Kidney Diseases.N6-甲基腺嘌呤RNA甲基化表观遗传修饰与肾脏疾病
Kidney Int Rep. 2022 Oct 17;8(1):36-50. doi: 10.1016/j.ekir.2022.10.009. eCollection 2023 Jan.
3
Epigenetic Changes in Diabetes and Cardiovascular Risk.糖尿病与心血管风险中的表观遗传变化。
Circ Res. 2016 May 27;118(11):1706-22. doi: 10.1161/CIRCRESAHA.116.306819.
4
Epigenetic regulation in diabetic vascular complications.糖尿病血管并发症的表观遗传调控。
J Mol Endocrinol. 2019 Nov;63(4):R103-R115. doi: 10.1530/JME-19-0170.
5
Role of m6A methylation in retinal diseases.m6A 甲基化在视网膜疾病中的作用。
Exp Eye Res. 2023 Jun;231:109489. doi: 10.1016/j.exer.2023.109489. Epub 2023 Apr 20.
6
Role of long noncoding RNAs in diabetes-associated peripheral arterial disease.长链非编码 RNA 在糖尿病相关外周动脉疾病中的作用。
Cardiovasc Diabetol. 2024 Jul 24;23(1):274. doi: 10.1186/s12933-024-02327-7.
7
Recent Advances on DNA Base Flipping: A General Mechanism for Writing, Reading, and Erasing DNA Modifications.DNA 碱基翻转的最新进展：一种用于写入、读取和擦除 DNA 修饰的通用机制。
Adv Exp Med Biol. 2022;1389:295-315. doi: 10.1007/978-3-031-11454-0_12.
8
The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms.成纤维细胞生长因子 21 在糖尿病心血管并发症及相关表观遗传机制中的作用
Front Endocrinol (Lausanne). 2021 Jul 19;12:598008. doi: 10.3389/fendo.2021.598008. eCollection 2021.
9
NRF2-Related Epigenetic Modifications in Cardiac and Vascular Complications of Diabetes Mellitus.NRF2 相关的表观遗传修饰在糖尿病心脏和血管并发症中的作用。
Front Endocrinol (Lausanne). 2021 Jun 25;12:598005. doi: 10.3389/fendo.2021.598005. eCollection 2021.
10
The potential role of m6A RNA methylation in diabetic retinopathy.m6A RNA 甲基化在糖尿病视网膜病变中的潜在作用。
Exp Eye Res. 2021 Jul;208:108616. doi: 10.1016/j.exer.2021.108616. Epub 2021 May 9.

引用本文的文献

1
RNA Modification in Metabolism.新陈代谢中的RNA修饰
MedComm (2020). 2025 Mar 10;6(3):e70135. doi: 10.1002/mco2.70135. eCollection 2025 Mar.
2
Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.探索甲基化领域：表观基因组与m6A表转录组的动态相互作用
Mol Ther. 2025 Feb 5;33(2):447-464. doi: 10.1016/j.ymthe.2024.12.003. Epub 2024 Dec 9.

本文引用的文献

1
Chemical labelling for mA detection: opportunities and challenges.用于毫安检测的化学标记：机遇与挑战。
Fundam Res. 2021 Dec 24;2(1):56-58. doi: 10.1016/j.fmre.2021.11.034. eCollection 2022 Jan.
2
(-)-Epigallocatechin 3-gallate protects pancreatic β-cell against excessive autophagy-induced injury through promoting FTO degradation.（-）-表没食子儿茶素没食子酸酯通过促进 FTO 降解来保护胰岛β细胞免受过度自噬诱导的损伤。
Autophagy. 2024 Nov;20(11):2460-2477. doi: 10.1080/15548627.2024.2370751. Epub 2024 Jul 3.
3
Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis.
骨髓间充质干细胞通过调节 Smad2/3/WTAP/m6A/ENO1 轴介导糖尿病肾病进展。
FASEB J. 2024 Jun 15;38(11):e23729. doi: 10.1096/fj.202301773R.
4
Targeting the mA RNA methyltransferase METTL3 attenuates the development of kidney fibrosis.靶向 mA RNA 甲基转移酶 METTL3 可减轻肾脏纤维化的发展。
Exp Mol Med. 2024 Feb;56(2):355-369. doi: 10.1038/s12276-024-01159-5. Epub 2024 Feb 1.
5
Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy.乳糖酰化驱动的 FTO 靶向 CDK2 加重糖尿病性视网膜病变中的微血管异常。
EMBO Mol Med. 2024 Feb;16(2):294-318. doi: 10.1038/s44321-024-00025-1. Epub 2024 Jan 31.
6
Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner.METTL3基因沉默通过以m6A依赖的方式介导WISP1，抑制高糖诱导的HK2细胞增殖、迁移、上皮-间质转化及肾纤维化。
Aging (Albany NY). 2024 Jan 29;16(2):1237-1248. doi: 10.18632/aging.205401.
7
N6-Methyladenosine Modification of lncCCKAR-5 Regulates Autophagy in Human Umbilical Cord Mesenchymal Stem Cells by Destabilizing LMNA and Inhibits Diabetic Wound Healing.N6-甲基腺苷修饰 lncCCKAR-5 通过稳定 LMNA 抑制自噬并抑制糖尿病伤口愈合。
J Invest Dermatol. 2024 May;144(5):1148-1160.e15. doi: 10.1016/j.jid.2023.11.023. Epub 2024 Jan 17.
8
Fat mass and obesity-associated (FTO) gene is essential for insulin secretion and β-cell function: In vitro studies using INS-1 cells and human pancreatic islets.脂肪量和肥胖相关（FTO）基因对于胰岛素分泌和β细胞功能至关重要：使用 INS-1 细胞和人胰腺胰岛的体外研究。
Life Sci. 2024 Feb 15;339:122421. doi: 10.1016/j.lfs.2024.122421. Epub 2024 Jan 15.
9
METTL14-mediated lncRNA XIST silencing alleviates GDM progression by facilitating trophoblast cell proliferation and migration via the miR-497-5p/FOXO1 axis.METTL14 介导的长链非编码 RNA XIST 沉默通过 miR-497-5p/FOXO1 轴促进滋养细胞增殖和迁移来减轻 GDM 的进展。
J Biochem Mol Toxicol. 2024 Jan;38(1):e23621. doi: 10.1002/jbt.23621.
10
IGF2BP3-stabilized CAMK1 regulates the mitochondrial dynamics of renal tubule to alleviate diabetic nephropathy.IGF2BP3 稳定的 CAMK1 调节肾小管的线粒体动力学，以减轻糖尿病肾病。
Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167022. doi: 10.1016/j.bbadis.2024.167022. Epub 2024 Jan 11.